Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

1.64 (USD) • At close September 18, 2024
Bedrijfsnaam Lexicon Pharmaceuticals, Inc.
Symbool LXRX
Munteenheid USD
Prijs 1.64
Beurswaarde 592,846,880
Dividendpercentage 0%
52-weken bereik 0.92 - 3.73
Industrie Biotechnology
Sector Healthcare
CEO Mr. Lonnel Coats
Website https://www.lexpharma.com

An error occurred while fetching data.

Over Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase

Vergelijkbare Aandelen

AlloVir, Inc. logo

AlloVir, Inc.

ALVR

0.76 USD

Dyne Therapeutics, Inc. logo

Dyne Therapeutics, Inc.

DYN

34.34 USD

4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc.

FDMT

16.82 USD

ClearPoint Neuro, Inc. logo

ClearPoint Neuro, Inc.

CLPT

11.66 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)